Managing Regimen Switch & Simplification

Module 8, Version 4

References

  • Aboud M, et al. Dolutegravir Versus Ritonavir-Boosted Lopinavir Both With Dual Nucleoside Reverse Transcriptase Inhibitor Therapy in Adults With HIV-1 Infection in Whom First-Line Therapy Has Failed (DAWNING): An Open-Label, Non-Inferiority, Phase 3b Trial. Lancet Infect Dis. 2019 Mar;19(3):253-264.
  • Aboud M, Orkin C, Podzamczer D, et al. Efficacy and safety of dolutegravir-rilpivirine for maintenance of virological suppression in adults with HIV-1: 100-week data from the randomised, open-label, phase 3 SWORD-1 and SWORD-2 studies. Lancet HIV. 2019;6(9):e576-e587.
  • Arribas JR, DeJesus E, van Lunzen J, et al. Simplification to single-tablet regimen of elvitegravir, cobicistat, emtricitabine, tenofovir DF from multi-tablet ritonavir-boosted protease inhibitor plus coformulated emtricitabine and tenofovir DF regimens: week 96 results of STRATEGY-PI. HIV Clin Trials. 2017;18(3):118-125.
  • Arribas JR, Girard PM, Landman R, et al. Dual treatment with lopinavir-ritonavir plus lamivudine versus triple treatment with lopinavir-ritonavir plus lamivudine or emtricitabine and a second nucleos(t)ide reverse transcriptase inhibitor for maintenance of HIV-1 viral suppression (OLE): a randomised, open-label, non-inferiority trial. Lancet Infect Dis. 2015;15(7):785-792.
  • Arribas JR, Pialoux G, Gathe J, et al. Simplification to coformulated elvitegravir, cobicistat, emtricitabine, and tenofovir versus continuation of ritonavir-boosted protease inhibitor with emtricitabine and tenofovir in adults with virologically suppressed HIV (STRATEGY-PI): 48 week results of a randomised, open-label, phase 3b, non-inferiority trial. Lancet Infect Dis. 2014;14(7):581-589.
  • Baxter JD, Mayers DL, Wentworth DN, et al. A randomized study of antiretroviral management based on plasma genotypic antiretroviral resistance testing in patients failing therapy. AIDS. 2000;14:F83-F93.
  • Borghetti A, Baldin G, Lombardi F, et al. Efficacy and tolerability of lamivudine plus dolutegravir as a switch strategy in a multicentre cohort of patients with suppressed HIV-1 replication. HIV Med. 2018;19(7):452-454.
  • Bunupuradah T, Chetchotisakd P, Ananworanich J, et al. A randomized comparison of second-line lopinavir/ritonavir monotherapy versus tenofovir/lamivudine/lopinavir/ritonavir in patients failing NNRTI regimens: The HIV STAR study. Antivir Ther. 2012;17:1351-1361.
  • Castagna A, Maggiolo F, Penco G, et al. Dolutegravir in antiretroviral-experienced patients with raltegravir- and/or elvitegravir-resistant HIV-1: 24-week results of the phase III VIKING-3 study. J Infect Dis. 2014;210: 354-362.
  • Cohen CJ, Hunt S, Sension M, et al. A randomized trial assessing the impact of phenotypic resistance testing on antiretroviral therapy. AIDS. 2002;16:579-588.
  • Daar E, DeJesus E, Ruane P, et al. Efficacy and safety of switching to fixed-dose bictegravir, emtricitabine, and tenofovir alafenamide from boosted protease inhibitor-based regimens in virologically suppressed adults with HIV-1: 48 weeks results of a randomised, open-label, multicentre, phase 3, non-inferiority trial. Lancet HIV. 2018 Jul;5(7):e347-e356.
  • Deeks SG, Wrin T, Liegler T, et al. Virologic and immunologic consequences of discontinuing combination antiretroviral-drug therapy in HIV-infected patients with detectable viremia. N Engl J Med. 2001;344(7):472-480.
  • DeJesus, et al. Superior Efficacy and Improved Renal and Bone Safety After Switching From a Tenofovir Disoproxil Fumarate- To a Tenofovir Alafenamide-Based Regimen Through 96 Weeks of Treatment. AIDS Res Hum Retroviruses. 2018 Apr;34(4):337-342.
  • DeJesus, et al. Switching From Efavirenz, Emtricitabine, and Tenofovir Disoproxil Fumarate to Tenofovir Alafenamide Coformulated With Rilpivirine and Emtricitabine in Virally Suppressed Adults With HIV-1 Infection: A Randomised, Double-Blind, Multicentre, Phase 3b, Non-Inferiority Study. Lancet HIV. 2017 May;4(5):e205-e213.
  • Derrick C, Ostermann J, Weissmann SB, et al. Who wants to switch? Gauging interest in potential new antiretroviral therapies. Open Forum Infect Dis. 2018 Oct 22;5(10):ofy247.
  • Doyle T, Dunn D, Ceccherini-Silberstein F, et al. Integrase inhibitor (INI) genotypic resistance in treatment-naïve and raltegravir-experienced patients infected with diverse HIV-1 clades. J Antimicrob Chemother. 2015;70:3080-3086.
  • Durant J, Clevenbergh P, Halfon P, et al. Drug-resistance genotyping in HIV-1 therapy: The VIRADAPT randomised controlled trial. Lancet. 1999;353:2195-2199.
  • Emu B, Fessel WJ, Schrader S, et al. Phase 3 Study of Ibalizumab for Multidrug-Resistant HIV-1. N Engl J Med. 2018 Aug 16;379(7):645-654.
  • Eron JJ, Cooper DA, Steigbigel RT, et al. Efficacy and safety of raltegravir for treatment of HIV for 5 years in the BENCHMRK studies: final results of two randomised, placebo-controlled trials. Lancet Infect Dis. 2013;13(7):587-596.
  • Eron JJ, Orkin C, Cunningham D, et al. Week 96 Efficacy and Safety Results of the Phase 3, Randomized EMERALD Trial to Evaluate Switching From Boosted-Protease Inhibitors Plus Emtricitabine/Tenofovir Disoproxil Fumarate Regimens to the Once Daily, Single-Tablet Regimen of Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (D/C/F/TAF) in Treatment-Experienced, Virologically-Suppressed Adults Living With HIV-1. Antiviral Res. 2019;170:104543.
  • Eron JJ, Young B, Cooper DA, et al. Switch to a raltegravir-based regimen versus continuation of a lopinavir-ritonavir-based regimen in stable HIV-infected patients with suppressed viremia (SWITCHMRK 1 and 2): Two multicentre, double-blind, randomised controlled trials. Lancet. 2010;375:396-407.
  • Fabbiani M, Gagliardini R, Ciccarelli N, et al. Atazanavir/ritonavir with lamivudine as maintenance therapy in virologically suppressed HIV-infected patients: 96 week outcomes of a randomized trial. J Antimicrob Chemother. 2018;73(7):1955-1964.
  • Gallant J, Lazzarin A, Mills A, et al. Bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir, abacavir, and lamivudine for initial treatment of HIV-1 infection (GS-US-380-1489): a double-blind, multicentre, phase 3, randomised controlled non-inferiority trial. Lancet. 2017;390(10107):2063-2072.
  • Gallant JE, Daar ES, Raffi F, et al. Efficacy and safety of tenofovir alafenamide versus tenofovir disoproxil fumarate given as fixed-dose combinations containing emtricitabine as backbones for treatment of HIV-1 infection in virologically suppressed adults: a randomised, double-blind, active-controlled phase 3 trial. Lancet HIV. 2016;3(4):e158-165.
  • Gatell JM, Assoumou L, Moyle G, et al. Switching From a Ritonavir-Boosted Protease Inhibitor to a Dolutegravir-Based Regimen for Maintenance of HIV Viral Suppression in Patients With High Cardiovascular Risk. AIDS. 2017;31(18):2503-2514.
  • Ghosn J, Carosi G, Moreno S, et al. Unboosted atazanavir-based therapy maintains control of HIV type-1 replication as effectively as a ritonavir-boosted regimen. Antivir Ther. 2010;15(7):993-1002.
  • Hagins D, Orkin C, Daar ES, et al. Switching to coformulated rilpivirine (RPV), emtricitabine (FTC) and tenofovir alafenamide from either RPV, FTC and tenofovir disoproxil fumarate (TDF) or efavirenz, FTC and TDF: 96-week results from two randomized clinical trials. HIV Med. 2018;19(10):724-733.
  • Hodder S, Squires K, Kityo C, et al. Brief Report: Efficacy and safety of switching to coformulated elvitegravir, cobicistat, emtricitabine, and tenofovir alafenamide (E/C/F/TAF) in virologically suppressed women. J Acquir Immune Defic Syndr. 2018;78(2):209-213.
  • Huhn GD, Eron JJ, Girard P-M, et al. Darunavir/cobicistat/emtricitabine/tenofovir Alafenamide in Treatment-Experienced, Virologically Suppressed Patients With HIV-1: Subgroup Analyses of the Phase 3 EMERALD Study. AIDS Res Ther. 2019 Aug 29;16(1):23.
  • Huhn GD, Tebas, P, Gallant J, et al. A randomized, open-label trial to evaluate switching to elvitegravir/cobicistat/ emtricitabine/tenofovir alafenamide plus darunavir in treatment-experienced HIV-1-infected adults. J Acquir Immune Defic Syndr. 2017;74:193-200.
  • Johnson M, Kumar P, Molina JM, et al. Switching to doravirine/lamivudine/tenofovir disoproxil fumarate (DOR/3TC/TDF) maintains HIV-1 virologic suppression through 48 weeks: results of the DRIVE-SHIFT trial. J Acquir Immune Defic Syndr. 2019;81(4):463-472.
  • Joly V, Burdet C, Landman R, et al. Dolutegravir and lamivudine maintenance therapy in HIV-1 virologically suppressed patients: results of the ANRS 167 trial (LAMIDOL). J Antimicrob Chemother. 2019;74(3):739-745.
  • Kityo C, Hagins D, Koenig E, et al. Switching to fixed-dose bictegravir, emtricitabine, and tenofovir alafenamide (B/F/TAF) in virologically suppressed HIV-1 infected women: a randomized, open-label, multicenter, active-controlled, phase 3, noninferiority trial. J Acquir Immune Defic Syndr. 2019;82(3):321-328.
  • Kozal M, et al. Fostemsavir in adults with multidrug-resistant HIV-1 infection. N Engl J Med. 2020;382(13):1232-1243.
  • Lathouwers E, De Meyer S, Dierynck I, et al. Virological characterization of patients failing darunavir/ritonavir or lopinavir/ritonavir treatment in the ARTEMIS study: 96-week analysis. Antivir Ther. 2011;16:99-108.
  • Llibre JM, Hung CC, Brinson C, et al. Efficacy, safety and tolerability of dolutegravir-rilpivirine for the maintenance of virological suppression in adults with HIV-1: phase 3, randomised, non-inferiority SWORD-1 and SWORD-2 studies. Lancet. 2018 Mar 3;391(10123):839-849.
  • Maggiolo F, Gulminetti R, Pagnucco L, et al. Lamivudine/dolutegravir dual therapy in HIV-infected, virologically suppressed patients. BMC Infect Dis. 2017;17(1):215.
  • Mallolas J, Podzamczer D, Milinkovic A, et al. Efficacy and safety of switching from boosted lopinavir to boosted atazanavir in patients with virological suppression receiving a LPV/r-containing HAART: The ATAZIP study. J Acquir Immune Defic Syndr. 2009;51:29-36.
  • Mallon P, Brunet L, Hsu R, et al. Weight gain before and after switch from TDF to TAF. J Int AIDS Soc. 2020;23(suppl 4):25-26. Abstract OAB0604.
  • Martin A, Bloch M, Amin J, et al. Simplification of antiretroviral therapy with tenofovir-emtricitabine or abacavir-lamivudine: A randomized, 96-week trial. Clin Infect Dis. 2009;49:1591-1601.
  • Martinez E. The NEFA study: Results at three years. AIDS Rev. 2007; 9:62.
  • McGovern RA, Thielen A, Mo T, et al. Population-based V3 genotypic tropism assay: A retrospective analysis using screening samples from the A4001029 and MOTIVATE studies. AIDS. 2010;24:2517-25.
  • Mills A, Arribas JR, Andrade-Villanueva J, et al. Switching from a tenofovir disoproxil fumarate to tenofovir alafenamide in antiretroviral regimens for virologically suppressed adults with HIV-1 infection: a randomised, active-controlled, multicentre, open label, phase 3, non-inferiority study. Lancet Infect Dis. 2016 Jan;16(1):43-52.
  • Mills AM, Cohen C, Dejesus E, et al. Efficacy and safety 48 weeks after switching from efavirenz to rilpivirine using emtricitabine/tenofovir disoproxil fumarate-based single-tablet regimens. HIV Clin Trials. 2013;14(5):216-223.
  • Molina JM, Ward D, Brar I, et al. Switching to fixed-dose bictegravir, emtricitabine, and tenofovir alafenamide from dolutegravir plus abacavir and lamivudine in virologically suppressed adults with HIV-1: 48 week results of a rand-omised, double-blind, multicentre, active-controlled, phase 3, non-inferiority trial. Lancet HIV. 2018 Jul:5(7):e357-e365.
  • Orkin C, Arastéh K, Hernández-Mora MG, et al. Long-Acting Cabotegravir and Rilpivirine After Oral Induction for HIV-1 Infection. N Engl J Med. 2020 Mar 19;382(12):1124-1135.
  • Orkin C, DeJesus E, Ramgopal M, et al. Switching From Tenofovir Disoproxil Fumarate to Tenofovir Alafenamide Coformulated With Rilpivirine and Emtricitabine in Virally Suppressed Adults With HIV-1 Infection: A Randomised, Double-Blind, Multicentre, Phase 3b, Non-Inferiority Study. Lancet HIV. 2017 May;4(5):e195-e204.
  • Orkin C, Molina J-M, Negredo E, et al. Efficacy and Safety of Switching From Boosted Protease Inhibitors Plus Emtricitabine and Tenofovir Disoproxil Fumarate Regimens to Single-Tablet Darunavir, Cobicistat, Emtricitabine, and Tenofovir Alafenamide at 48 Weeks in Adults With Virologically Suppressed HIV-1 (EMERALD): A Phase 3, Randomised, Non-Inferiority Trial. Lancet HIV. 2018 Jan;5(1):e23-e34.
  • Palella FJ Jr, Fisher M, Tebas P, et al. Simplification to rilpivirine/emtricitabine/tenofovir disoproxil fumarate from ritonavir-boosted protease inhibitor antiretroviral therapy in a randomized trial of HIV-1 RNA-suppressed participants. AIDS. 2014;28(3):335-344.
  • Paton NI, Kityo C, Hoppe A, et al. Assessment of second-line antiretroviral regimens for HIV therapy in Africa. N Engl J Med. 2014 Jul 17;371(3):234-47.
  • Perez-Molina JA, Rubio R, Rivero A, et al. Dual treatment with atazanavir-ritonavir plus lamivudine versus triple treatment with atazanavir-ritonavir plus two nucleos(t)ides in virologically stable patients with HIV-1 (SALT): 48 week results from a randomised, open-label, non-inferiority trial. Lancet Infect Dis. 2015;15(7):775-784.
  • Pett SL, Amin J, Horban A, et al. Week 96 results of the randomized, multicentre Maraviroc Switch (MARCH) study. HIV Med. 2018;19(1):65-71.
  • Pierone G, Henegar C, Fusco J, et al. Two-drug Antiretroviral Regimens: An Assessment of Virologic Response and Durability Among Treatment-Experienced Persons Living With HIV in the OPERA ® Observational Database. J Int AIDS Soc. 2019;22(12):e25418.
  • Pozniak A, Arribas JR, Gathe J, et al. Switching to tenofovir, coformulated with elvitegravir, cobicistat, and emtricitabine, in HIV-infected patients with renal impairment: 48-week results from a single-arm, multicenter, open-label phase III study. J Acquir Immune Defic Syndr. 2016;71:530-537.
  • Pozniak A, Markowitz M, Mills A, et al. Switching to coformulated elvitegravir, cobicistat, emtricitabine, and tenofovir versus continuation of non-nucleoside reverse transcriptase inhibitor with emtricitabine and tenofovir in virologically suppressed adults with HIV (STRATEGY-NNRTI): 48 week results of a randomised, open-label, phase 3b non-inferiority trial. Lancet Infect Dis. 2014;14(7):590-599.
  • Pulido F, Ribera E, Lagarde M, et al. Dual therapy with darunavir and ritonavir plus lamivudine versus triple therapy with darunavir and ritonavir plus tenofovir disoproxil fumarate and emtricitabine or abacavir and lamivudine for maintenance of HIV-1 viral suppression: randomised, open label, non-inferiority DUAL-GESIDA 8014-RIS-EST45 trial. Clin Infect Dis. 2017;65(12):2112-2118.
  • Raffi F, Orkin C, Clarke A, et al. Brief report: long-term (96-week) efficacy and safety after switching from tenofovir disoproxil fumarate to tenofovir alafenamide in HIV-infected, virologically suppressed adults. J Acquir Immune Defic Syndr. 2017;75: 226–231.
  • Ramgopal M, Maggiolo M, Ward F, et al. Pooled analysis of 4 international trials of bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) in adults aged >65 or older demonstrating safety and efficacy: week 48 results. J Int AIDS Soc. 2020;23(suppl 4):18. Abstract OAB0403.
  • Saag MS, Benson CA, Gandhi RT, et al. Antiretroviral drugs for treatment and prevention of HIV infection in adults. 2018 recommendations of the International Antiviral Society-USA panel. JAMA. 2018;320(4):379-396.
  • Sax PE, Pozniak A, Montes ML, et al. Coformulated bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir with emtricitabine and tenofovir alafenamide, for initial treatment of HIV-1 infection (GS-US-380-1490): a randomised, double-blind, multicentre, phase 3, non-inferiority trial. Lancet. 2017;390(10107):2073-2082.
  • Second-Line Study Group, Boyd MA, Kumarasamy N, et al. Ritonavir-boosted lopinavir plus nucleoside or nucleotide reverse transcriptase inhibitors versus ritonavir-boosted lopinavir plus raltegravir for treatment of HIV-1 infection in adults with virological failure of a standard first-line ART regimen (SECOND-LINE): A randomised, open-label, non-inferiority study. Lancet. 2013;381:2091-2099.
  • Squires KE, Young B, DeJesus E, et al. ARIES 144 week results: durable virologic suppression in HIV-infected patients simplified to unboosted atazanavir/abacavir/lamivudine. HIV Clin Trials. 2012;13(5):233-244.
  • Stebbing J, Nathan B, Jones R, et al. Virological failure and subsequent resistance profiles in individuals exposed to atazanavir. AIDS. 2007;21:1826-1828.
  • Swindells S, Andrade-Vallanueva JF, Richmond GJ, et al. Long-Acting Cabotegravir and Rilpivirine for Maintenance of HIV-1 Suppression. N Engl J Med. 2020 Mar 19;382(12):1112-1123.
  • Taiwo BO, Marconi VC, Berzins B, et al. Dolutegravir plus lamivudine maintains human immunodeficiency virus-1 suppression through Week 48 in a pilot randomized trial. Clin Infect Dis. 2018;66(11):1794-1797.
  • Tashima KT, Smeaton LM, Fichtenbaum CJ, et al. HIV salvage therapy does not require nucleoside reverse transcriptase inhibitors: A randomized, controlled trial. Ann Intern Med. 2015;163:908-917.
  • Tasias M, Viciana P, Deig E, et al. Reasons for antiretroviral treatment changes in Spanish HIV 1 patients in 2011: SWITCH AUDIT study. J of the Intl AIDS Soc. 2012; 15(Suppl 4):18345.
  • vanWyk J, Ajana F, Bisshop F, et al. Efficacy and Safety of Switching to Dolutegravir/Lamivudine Fixed-Dose Two-Drug Regimen Versus Continuing a Tenofovir Alafenamide-Based Three- Or Four-Drug Regimen for Maintenance of Virologic Suppression in Adults With HIV-1: Phase 3, Randomized, Non-inferiority TANGO Study. Clin Infect Dis. 2020 Jan 6;ciz1243. Online ahead of print.
  • White KL, Raffi F, Miller MD. Resistance analyses of integrase strand transfer inhibitors within phase III clinical trials of treatment-naïve patients. Viruses. 2014;6:2858-2879.
  • Winston A, Post FA, DeJesus E, et al. Tenofovir alafenamide plus emtricitabine versus abacavir plus lamivudine for treatment of virologically suppressed HIV-1-infected adults: a randomised, double-blind, active-controlled, non-inferiority phase 3 trial. Lancet HIV. 2018;5(4):e162-e171.
  • Wohl DA, Bhatti L, Small CB, et al. The ASSURE study: HIV-1 suppression is maintained with bone and renal biomarker improvement 48 weeks after ritonavir discontinuation and randomized switch to abacavir/lamivudine + atazanavir. HIV Med. 2016;17(2):106-117.
  • Aboud M, Orkin C, Podzamczer D, et al. Durable suppression 2 years after switch to DTG + RPV 2-drug regimen: SWORD 1&2 studies. 22nd IAS Conference: July 23-27, 2018. Amsterdam, The Netherlands. Abstract THPEB047.
  • Brown D, Wang R, Underwood M, et al. DTG vs LPV/R (DAWNING): Efficacy by Baseline NRTI Resistance and Second-line NRTI Use. CROI 2018. CROI 2019. Abstract 144.
  • Emu B, DeJesus E, Berhe M, et al. Ibalizumab efficacy and safety through 48 weeks of treatment: results of an expanded access protocol (TMB-311). ID Week 2019. October 2-6; Washington, DC. Abstract 661.
  • Eron JJ, Orkin C, Molina JM, et al. Analysis of HIV patients switching to D/C/F/T by prior ARV treatment experience. CROI 2018. March 4-7, 2018. Boston, MA. Abstract 502.
  • Kumar P, Johnson M, Xu ZJ, et al. Weight changes after switch to doravirine/lamivudine/TDF in the DRIVE-SHIFT trial. J Int AIDS Soc. 2020;23(suppl 4):26-27. Abstract OAB0605.
  • Lataillade M, Lalezari J, Aberg J, et al. Week 96 safety and efficacy of the novel HIV-1 attachment inhibitor prodrug fostemsavir in heavily treatment-experienced participants infected with multi-drug resistant HIV-1 (BRIGHTE study). 10th IAS Conference on HIV Science (IAS 2019), July 21-24, 2019, Mexico City. Abstract MOAB0102.
  • Nichols G, Lazzarin A, Maggiolo F, et al. Phase III assessment of dolutegravir (DTG) 50 mg twice daily (BID) in HIV-1 infected subjects with raltegravir (RAL) and/or elvitegravir (EVG) resistance in VIKING-3: Week 24 results of all 183 subjects enrolled. IAS 2013, Kuala Lumpur, Malaysia. Poster TULBPE19.
  • Orkin C, Arastéh K, Hernández-Mora MG, et al. Long-acting cabotegravir + rilpivirine for HIV maintenance: FLAIR week 48 results. 2019 CROI. March 4-7, 2019. Seattle, WA. Abstract 140.
  • Orkin C, Oka S, Philibert P, et al. Long-acting cabotegravir + rilpivirine for HIV treatment: FLAIR week 96 results. CROI 2020. March 8-11, 2020. Boston, Massachusetts. Abstract 482.
  • Overton ET, Richmond G, Rizzardni G, et al. Cabotegravir + rilpivirine every 2 months is noninferior to monthly: ATLAS-2m study. CROI 2020. March 8-11, 2020. Boston, Massachusetts. Abstract 34.
  • Santoro M, et al. Susceptibility to Bictegravir in Highly ARV-Experienced Patients After INSTI Failure. CROI 2019. March 4-7, 2019. Seattle, Washington. Abstract 550.
  • Spinner C, Kümmerle T, Schneider J, et al. A switch to dolutegravir in combination with boosted darunavir is safe and effective in suppressed patients with HIV—a subanalysis of the dualis study. Presented at: IAS Conference on HIV Science. 2019. Mexico City, Mexico. Abstract MOPEB269.
  • Swindells S, Andrade-Vallanueva JF, Richmond GJ, et al. Long-acting cabotegravir + rilpivirine as maintenance therapy: ATLAS week 48 results. CROI 2019. March 4-7, 2019. Seattle, WA. Abstract 139.

Thank you for visiting the AAHIVM Provider Education Center! 

In order to continue, we will need you to create a profile. This will help us keep track of your education activity and CME accreditations.

           NEW USERS CLICK HERE TO CREATE A PROFILE.           

ALREADY CREATED YOUR AAHIVM PROFILE? CLICK HERE TO SIGN IN.

Are you an AAHIVM member? If not, consider supporting the Academy and programs like these. Click here to become an Academy member.

 

Connect

Phone: 202-659-0699
Fax: 202-659-0976

Contact

AAHIVM National Office
1627 Eye St NW Suite 835
Washington, D.C. 20006

About

The American Academy of HIV Medicine is a professional organization that supports the HIV practitioner and promotes accessible, quality care for all Americans living with HIV disease. Our membership of HIV practitioners and credentialed HIV Specialists™, HIV Experts™, and HIV Pharmacists™ provide direct care to the majority of HIV patients in the US.